1.2500
07-10月-24 15:59:55
15 分の遅延
株式
-0.0100
-0.79%
本日の幅
1.2000 - 1.3100
ISIN
N/A
ソース
NASDAQ
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
07 11 2023 08:00:01 提供 Nasdaq GlobeNewswire
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
16 10 2023 07:00:27 提供 Nasdaq GlobeNewswire
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
04 10 2023 08:30:00 提供 Nasdaq GlobeNewswire